ONCOLYZE, INC.

NEW YORK, NY · Digital health · Still private

AI-powered software for analyzing oncology data and optimizing cancer treatment decisions

Claim this profile

Follows are private to you and power your alerts

Updated · oncolyze.ai

Sector
Digital health
Headquarters
NEW YORK, NY
Latest Form D
$425K, Jul 2022
Total capital
$425K
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$425K
1 Form D · last Jul 2022
52 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
1
8 pending · first 2025
Rank in peer group#28 of 197

Capital timeline

2022FEDERAL ↑EQUITY ↓Cumulative $425K1st Form D$425K
2022FEDERAL ↑EQUITY ↓Cumulative $425K1st Form D$425K

Latest events

  • Private capital raisedForm D · SEC · 1st filing$425K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 197 peers

Line = median

Digital health · Software

  • Granted patents#28 · top 14%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Steven J. EvansResearcherExecutive Officer, DirectorLinked by 1 patent
  • Aleksandar J. StojanovicExecutive OfficerNamed in SEC Form D filings
  • Alexander J. ZukiwskiDirectorNamed in SEC Form D filings
  • Barbara J. CarlinExecutive OfficerNamed in SEC Form D filings
  • James J. FoghtDirectorNamed in SEC Form D filings
  • John J. AbelesDirectorNamed in SEC Form D filings
Show all 8 people
  • Larry J. AltstielExecutive OfficerNamed in SEC Form D filings
  • Rosemary J. MazanetDirectorNamed in SEC Form D filings

What it has protected

USPTO · 1 granted of 9
Show all 9 patent records
  • Compositions For Use In Lysis Of Selective Cancer CellsMar 4, 2025 · US 12,239,720Granted
  • Stable Formulations Of Anti-cancer PeptidesNov 2, 2023 · Application 18016855Pending
  • HDM2 Antibody For Use In Treating CancerMay 19, 2022 · Application 17432563Pending
  • Stable Formulations of Anti-Cancer PeptidesApplication 62957531Pending
  • Compositions For Use In Lysis Of Selective Cancer CellsApplication PCTUS2019026390Pending
  • HDM2 Antibody For Use In Treating CancerApplication 62808073Pending
  • Compositions For Use In Lysis Of Selective Cancer CellsApplication 62653808Pending
  • Stable Formulations Of Anti-cancer PeptidesApplication PCTUS2020067161Pending
  • HDM2 Antibody For Use In Treating CancerApplication PCTUS2020018552Pending
  • SABI Mind Inc.Similar federal contract value in Digital health · null in contracts
  • Justpoint Inc.Similar federal contract value in Digital health · null in contracts
  • NeuTigers, Inc.Similar federal contract value in Digital health · null in contracts
  • Crate, Inc.Similar federal contract value in Digital health · null in contracts
  • Elmntri LLCSimilar federal contract value in Digital health · null in contracts
  • Adaya AI, Inc.Similar federal contract value in Digital health · null in contracts

Regulatory activity · Digital health

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .